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Abstract
Background: Exosomes are extracellular vesicles released by almost all cell types, including cancer cells, into bodily
fluids such as saliva, plasma, breast milk, semen, urine, cerebrospinal fluid, amniotic fluid, synovial fluid and sputum.
Their key function being intercellular communication with both neighbouring as well as distant cells. Cancer exosomes
have been shown to regulate organ-specific metastasis. However, little is known about the functional differences and
molecular consequences of normal cells responding to exosomes derived from normal cells compared to those
derived from cancer cells.
Methods: Here, we characterised and compared the transcriptome profiles of primary human normal oral keratinocytes
(HNOK) in response to exosomes isolated from either primary HNOK or head and neck squamous cell carcinoma (HNSCC)
cell lines.
Results: In recipient HNOK cells, we found that regardless of normal or cancer derived, exosomes altered molecular
programmes involved in matrix modulation (MMP9), cytoskeletal remodelling (TUBB6, FEZ1, CCT6A), viral/dsRNA-
induced interferon (OAS1, IFI6), anti-inflammatory (TSC22D3), deubiquitin (OTUD1), lipid metabolism and membrane
trafficking (BBOX1, LRP11, RAB6A). Interestingly, cancer exosomes, but not normal exosomes, modulated expression of
matrix remodelling (EFEMP1, DDK3, SPARC), cell cycle (EEF2K), membrane remodelling (LAMP2, SRPX), differentiation
(SPRR2E), apoptosis (CTSC), transcription/translation (KLF6, PUS7). We have also identified CEP55 as a potential cancer
exosomal marker.
Conclusions: In conclusion, both normal and cancer exosomes modulated unique gene expression pathways in normal
recipient cells. Cancer cells may exploit exosomes to confer transcriptome reprogramming that leads to cancer-associated
pathologies such as angiogenesis, immune evasion/modulation, cell fate alteration and metastasis. Molecular pathways
and biomarkers identified in this study may be clinically exploitable for developing novel liquid-biopsy based diagnostics
and immunotherapies.
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Background
Exosomes are extracellular nano-sized (< 150 nm) mem-
brane vesicles released by almost all cell types, including
cancer cells, into almost all bodily fluids. They are spher-
ical bilayered proteolipids harbouring specific proteins [1],
RNA [2] and DNA [3]. Non-coding RNA (microRNA,
siRNA and piRNA) and mRNA are key cargos of
exosomes [2]. Their key function being intercellular com-
munication with both neighbouring as well as distant cells
[2]. It has been suggested that tumour cells exploit this
intercellular communication mechanism to confer target
cell reprogramming that leads to cancer-associated path-
ologies such as angiogenesis, immune evasion/modula-
tion, cell fate alteration and metastasis. Emerging evidence
suggests that tumour viruses also exploit the exosomal
message delivery system to induce pathogenesis. Identifi-
cation of oncogenic exosomal RNA is prerequisite to the
understanding of tumour pathophysiology.
Protein composition of exosomes is informative of any
existing pathology as they can carry tumour antigens and
inflammatory mediators. They also carry customary
proteins including HSC70, TSG101 and tetraspanins [1],
in addition they carry specific proteins which are involved
in vesicle formation and trafficking such as ALIX (Apop-
tosis linked gene 2-interacting protein X) [4]. Exosomes
are enriched in tetraspanins, a family of proteins that or-
ganizes membrane microdomains called tertraspanin
enriched microdomains, by forming clusters and interact-
ing with transmembrane and cytosolic signalling proteins
[5]. Among tetraspanin CD9, CD63, CD81, CD82 and
CD151 have a broad tissue distribution. They are involved
in biological processes including cell adhesion, motility,
membrane fusion, signalling and protein trafficking [6].
Biogenesis of intraluminal vesicle (ILV, which later be-
come exosomes when excreted) involves endosomal sort-
ing complex required for transport (ESCRT). ESCRT
consist of approximately 20 proteins that assemble into
four complexes ESCRT-0, I, II and III with associated pro-
teins VPS4 (Vacuolar protein sorting- associated protein
4), VTA1 (vesicle trafficking 1) and ALIX forming ESCRT
accessory complex [7]. ESCRT-0 complex recognizes and
segregates ubiquitylated proteins in endosomal membrane.
ESCRT I and II deform the membrane into buds with se-
questered cargo. ESCRT III is responsible for cleavage into
free vesicles [8]. The mechanism by which ESCRT III
complex detaches ILV into multi-vesicular body is similar
to final cut between two dividing daughter cells [9]. Recent
studies have shown formation of a helix with a
centrosomal protein (CEP55), which translocates to the
mid-body during the late phase of cell division and func-
tions as a scaffold for components of the abscission
machinery. CEP55 interacts with ESCRT and ALIX-binding
region (EABR) [10]. Previously we have shown that CEP55
is a downstream target of FOXM1, an oncogene that
regulates cell cycle, DNA repair and maintenance of gen-
omic stability [11, 12]. This study investigated the presence
of CEP55 protein in normal and cancer exosomes.
The presence of exosomes in bodily fluids (eg., saliva)
represents a promising surrogate approach to investigate
tumour exosomal RNA biomarkers which has important
clinical implications for developing non-invasive salivary
diagnostics and therapeutics [13]. Human saliva is an
ideal fluid for developing non-invasive diagnostics and
salivary biomarkers have been demonstrated in clinical
studies showing promising diagnostic potentials but
lacking in sensitivity mostly due to complexity of saliva
[13]. Hence, the ability to purify the highly stable (RNA
cargo within exosomes are resistant to RNase [2]) and
protected biomolecules within exosomes helps in reducing
background noise in a highly complex and heterogeneous
environment such as saliva [13]. Most of the salivary
exosome studies to date have been restricted to
characterization of normal healthy samples [13]. Emerging
studies began looking at biochemical properties of disease-
derived saliva exosomes but most of these studies focused
on proteomics analysis [1, 13].
HNSCC is diagnosed in over half a million individuals
worldwide each year, with an expected global incidence of
750,000 by 2015 [14]. According to the 8th national
annual head and neck cancer audit report published by
UK Health and Social Care Information Centre, there
were 8272 cases within England and Wales in 2012. Sur-
vival rates are poor (10–30% at 5 years) among patients
presenting with advanced disease. Early detection of
precancer lesions coupled with early intervention could
significantly improve patient outcome, reduce mortality
and alleviate healthcare costs. Unfortunately, conventional
histopathology is currently unable to accurately identify
which individual lesions from the oral potentially malig-
nant disorders spectrum will transform to squamous cell
carcinoma (SCC). Given similar pathogenesis of other
epithelial SCCs, the same clinical dilemmas apply to the
management of vulva and skin premalignancies. Current
screening methods for HNSCC in otherwise symptom-free
persons include the use of oral cytology (brush biopsy),
toludine blue staining and various light-based detection
systems. More advanced screening methods such as saliv-
ary proteomics and antibody-based detection are under
investigation. However, the effectiveness of these oral
screening adjuncts in detecting early cancer remains un-
proven [15]. Hence, there is an urgent clinical need to ex-
plore novel cancer biomarkers with better sensitivity and
specificity. Salivary exosomal RNA represents a prom-
ising new avenue for developing a non-invasive
HNSCC screening tool [13]. In an attempt to identify
novel biomarkers for early detection of HNSCC, this study
characterised and investigated normal and cancer-derived
exosomes and their transcriptome modulating profiles
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Normal primary human oral keratinocytes were cultured in
serum free medium (SFM) containing 15 ng/ml of human
recombinant epidermal growth factor cat no. 10450–013),
62.5 μg/ml bovine pituitary extract (cat no. 13028–014)
and 1% penicillin/streptomycin (cat no. 15070–063 from
Life technologies UK). HNSCC and transformed cell lines
were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% foetal bovine serum (FBS) (cat no.
02–00-850, from First Link Ltd. UK) and 1% penicillin/
streptomycin. All cells were cultured in a humidified incu-
bator with 5% CO2/95% atmospheric air at 37 °C. Due to
the abundance of bovine exosomes in FBS, we have found
that human exosomes, although still detectable (by qPCR
against specific human markers), were partially masked by
the much larger quantity of bovine exosomes (data not
shown). Hence, for cells grown in FBS-containing DMEM,
to prevent contamination from bovine exosomes, once cells
reached ~ 90% confluent (~ 2 × 107 cells in a 175 cm2
flask), we switched to culturing cells in SFM. All cells were
left to grow in SFM for 3 days prior to exosome isolation.
Additional information regarding each cell line used in this
study can be found in (Additional file 1).
Isolation of exosomes by ultracentrifugation
Exosomes were isolated from cell culture supernatant
according to well-established ultracentrifugation method
[5, 17, 18] with minor modification. Briefly, the condi-
tioned SFM supernatant was collected and centrifuged
in 50 mL tubes at the speed of 500×g for 10 min to re-
move cellular debris and apoptotic bodies. The super-
natant was then centrifuged (SORVALL® Discovery™ SE
ultracentrifuge with a SORVALL® T-865 Fixed 23.5°
Angle Rotor, k-factor = 51.7) at the speed of 16,500×g
for 20 mins to collect microvesicles. Special polycarbon-
ate high speed centrifuge tubes from Thermo Scientific
(cat. no. 314348) with screw cap lids (cat no. 314347)
were used for high speed ultracentrifugation. The super-
natant was filtered through a 0.22 μm filter to remove
protein and debris prior to ultracentrifugation at
118,000×g for 70 mins to pellet exosomes. The last
ultracentrifugation step was repeated to wash exosomes
pellet in PBS.
Scanning electron microscopy
Exosome pellet was re-suspended and fixed in PBS con-
taining 2.5% glutaraldehyde for 1 h at room temperature.
Fixed exosomes were washed by adding 20 mL PBS
followed by ultracentrifugation at 118000×g for 70 mins.
The exosome pallet was resuspended in 100 μl of PBS
and incubated on fibronectin-precoated 13 mm round
coverslips, without allowing the coverslips to dry, the sam-
ples were incubated overnight at 37 °C. Coverslips were
then dehydrated in ascending series of ethanol concentra-
tions from 30, 50, 70, 80, 90 to 95% for 5 mins each,
followed by two 5 mins incubations in 100% ethanol. The
samples were then chemically dried in 100% HMDS
(Hexamethyldisilazane) for 3 mins and allowed to air dry
at 37 °C for 30 mins. Double-sided adhesive carbon coated
conductive discs were used to secure the coverslips onto
the SEM stubs. A carbon conducting cement was used to
aid a conducting pathway between the stub and the cover-
slips. The cement was allowed to dry for 24 h prior to
coating with gold or carbon particles. Scanning electron
micrographs (at 0.5 to 30 kV) were obtained using an FEI
Inspect F system. The xT microscope control software
was used to control the operation of the microscope while
the image capturing software was used to obtain images.
SEM was supervised by Dr. Russell Bailey at the Nano
Vision centre, QMUL.
Transmission electron microscopy
Exosome pellet was resuspended and fixed in 100 μl of 4%
(w/v) paraformaldehyde for 10 mins and 5 μl of the fixed
exosomes were placed on carbon coated EM grids (Cata-
logue no. S160–4 carbon film, 400 Mesh Cu by Agar sci-
entific) for 20 mins. A drop of 100 μl of PBS on parafilm
sheet was used to wash the grid (membrane side down).
The grids were transferred to a 50 μl drop of 2.5% (w/v)
gluteraldehyde for 10 mins, followed by eight washes in
100 μl of molecular-grade DNase/RNase/Protease-free
water (W4502, Sigma-Aldrich) [16]. The samples were
stained by 0.4% (w/v) lead citrate for 1 min. Stained grids
were washed twenty times with distilled water and air
dried on filter paper. TEM was supervised by Dr. Russell
Bailey from Nano Vision centre QMUL.
Immuno-gold TEM
Exosomes were fixed in 100 μl of 4% (w/v) paraformalde-
hyde from which 5 μl was placed on carbon coated
electron microscopy grids. The grids were covered and left
for 20 mins to facilitate adsorption. Further, the grids were
washed in 100 μL drops of PBS and transferred in PBS/
50 mM ammonium chloride (NH4CL) for 3 mins. The
grids were transferred to blocking buffer (10% foetal calf
serum) for 10 mins followed by a transfer to 5 μl drops of
CEP55 antibody in the dilution of 1:50 in blocking buffer
for 30 mins. The grids were washed multiple times in
washing buffer for 3 mins. The grids were incubated with
secondary (bridging) antibody diluted in blocking buffer
for 30 mins and transferred to 100 μl drops of PBS/0.5%
BSA and washed 3 times. Further, the exosomes were in-
cubated in 5 μl drops of protein A-gold conjugates diluted
in blocking buffer for 20 mins followed by 7 washes in
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PBS. The grids were transferred to 50 μL drops of 1% glu-
taraldehyde for 5 mins to stabilize immunoreaction. The
grids were washed 7 times in 100 μl drops of double dis-
tilled water, each time for 2 mins. The samples were con-
trasted using uranyl oxalate at pH 7 for 5 mins.
Immuno-gold labelling was done by Dr. Giulia Mas-
troianni (TEM Facility Manager) at QMUL, following
published protocol [16].
Dynamic light scattering
Fractions of apoptotic cell debris (1st pellet following
500×g centrifugation), microvesicles (2nd pellet follow-
ing 16,500×g) and exosomes (3rd pellet following
118,000×g) were resuspended in 1 mL molecular grade
water for use in a Zetasizer Nano ZS instrument (Model:
ZEN3600, Serial no.: MAL500457, Malvern Instruments)
to measure the Brownian motion of particles in a sample
using Dynamic Light Scattering providing 3 fundamental
parameters of nano-sized particles or molecules in a li-
quid medium: particle size; zeta potential; and molecular
weight. The Zetasizer Nano ZS can measure: particle
size for the size range 0.6 nm to 6 μm; Zeta potential for
a size range 5 nm to 10 μm; Molecular weight in the size
range 1000 to 2 × 107 Da. All samples were read at 4 °C
and particle size was measured as intensity percent with
respect to diameter in nanometre (nm).
Nanoparticle tracking analysis
Particle size verification of exosomes was carried out in
School of Pharmacy, University College London using
NanoSight Nanoparticle Tracking Analysis (NTA Nano-
Sight, Malvern Inc., United Kingdom) [17, 18]. Samples
were prepared in 500 μl molecular-grade DNase/RNase/
Protease-free water (W4502, Sigma-Aldrich) and stored
at − 80 °C until use. Using a 1-mL syringe, samples were
loaded into the assembled sample chamber of the Nano-
Sight LM10. One minute video images were captured
with manual shutter and gain adjustments (Hamamatsu
C11440 ORCA-Flash 2.8 digital camera) and analysed
using the NanoSight NTA 2.0 software.
RNase protection assays and RNA isolation and quality
control
RNase, detergent and protease protection assays were
performed to investigate the origin of RNA whether it
was protected by exosomes and/or protein complexes.
Following ultracentrifugation, the supernatant was gently
aspirated and the exosome pellet was resuspended in
260 μL molecular grade water and subdivided into equal
fractions (50 μL) which received either: 1) vehicle (dH20),
2) RNase A digestion (0.6 mg/mL final concentration,
#R6513, SIGMA) (30 min at 37 °C), 3) detergent incubation
(2% Triton-X, 10 min at 55 °C) followed by RNase diges-
tion, 4) proteinase K digestion (PK, #03115828001, ~
0.4 mg/mL final concentration, Roche Diagnostics) (10 min
at 55 °C prior to 5 min heat inactivation at 95 °C) followed
by RNase digestion, 5) Triton-X and PK treatment
followed by RNase digestion. RNase activity was then
inactivated by adding RNase inhibitor (03335399001,
1 U/μl final, Roche, 5 mins at RT). Total RNA was
purified using RNeasy Micro Kit (#74004, Qiagen)
and quantified using Quan-iTTM RiboGreen® RNA
Assay kit (R11490, Molecular Probes, Life Technolo-
gies). RNA size, quality and relative quantity were
assessed by Agilent BioAnalyzer RNA 6000 Pico chip
(#5067–1513, Agilent Technologies, Germany). Our
typical exosomal RNA yield from each cell line sam-
ple (grown in 2× T157 flasks with a total of 80 mL
culture supernatant) was 1–4 ng (10–50 pg RNA/mL
supernatant). Given that on average each mL of
supernatant contains 1-5 × 107 particles (determined
by NTA), we estimated each exosome to contain
approximately 0.2-5 × 10−18g (attogram) RNA.
Reverse transcription-quantitative PCR (RT-qPCR)
Exosomal RNA were converted to cDNA using qPCRBIO
cDNA Synthesis kit (#PB30.11–10, PCRBIO Systems, UK)
and the cDNA was diluted 1:4 with RNase/DNase free
water and stored at − 20 °C until used for qPCR. Relative
quantitative PCR were performed using qPCRBIO
SyGreen Blue Mix Lo Rox (#PB20.11–50, PCRBIO Sys-
tems, UK) in the 384-well LightCycler 480 qPCR system
(Roche) according to our well-established protocols [11,
12, 19, 20] which are MIQE compliant [21]. Briefly, ther-
mocycling begins with 95 °C for 30s prior to 45 cycles of
amplification at 95 °C for 6 s, 60 °C for 6 s, 72 °C for 6 s,
76 °C for 1 s (data acquisition). A ‘touch-down’ annealing
temperature intervention (66 °C starting temperature with
a step-wise reduction of 0.6 °C/cycle; 8 cycles) was intro-
duced prior to the amplification step to maximise primer
specificity. Melting analysis (95 °C for 30s, 65 °C for 30s,
65–99 °C at a ramp rate of 0.11 °C/s with a continuous 1
acquisition/°C) was performed at the end of qPCR amplifi-
cation to validate single product amplification in each
well. Relative quantification of mRNA transcripts was cal-
culated based on an objective method using the second
derivative maximum algorithm (Roche). All target genes
were normalised to two stable reference genes (YAP1 and
POLR2A) validated previously to be uninfluenced by dis-
ease process [20]. For further verification and comparison,
some experiments were performed using Taqman gene
expression assays for FOXM1 (Hs1073586_m1), CEP55
(Hs01070181_m1) and ACTB (Hs01060665_g1) using
LightCycler® 480 Probes Master (#04707494001, Roche
Diagnostics) with a pre-incubation of 50 °C, 2 min and
95 °C, 10 min hot-start followed by 50 cycles of 95 °C, 10s
and 60 °C, 60s.
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Western blotting
Primary Antibody used were: Alix(3A9) (1:1000 dilution,
mouse monoclonal, mAb#2171, Cell Signalling), CD9
(1:200, rabbit monoclonal, ab92726, Abcam), CD63
(H-193) (1:1000, rabbit polyclonal, sc-15,363, Santa
Cruz), CEP55 (1:10000, rabbit monoclonal, ab170414,
Abcam), Calnexin (1:1000, rabbit polyclonal, ab22595,
Abcam), Glypican 1 (1:500, rabbit polyclonal, ab55971,
Abcam), FOXM1 (1:500, rabbit polyclonal, sc-502, Santa
Cruz), GAPDH (1:10000, mouse monoclonal, ab8245,
Abcam), HSC70(B-6) (1:10000, mouse monoclonal,
SC-7298, Santa Cruz). Secondary antibody used were:
Goat anti Rabbit IgG (1:1000; AP#132P, Millipore), Goat
Anti-Mouse IgG (1:10000, A0168, Sigma). Additional
information on immunoblotting methodology can be
found in (Additional file 1).
Microarray gene expression
Normal primary oral keratinocytes (OK113) cells were
seeded (1 × 105 per well) in 6-well plates 1 day prior to
transfection with exogenous exosomes derived from 3
normal oral keratinocytes (OK113, NK4, NOK368) and 5
malignant (Ca1, CaLH2, SQCC/Y1, SVpgC2a and SVFN8)
cell lines. Exosome concentrations were adjusted to 2 ×
1010 particles/well. Untreated OK113 cells were used as a
control. After 48 h of incubation with exosomes in SFM,
the cells were washed with 1 × PBS and lysed in lysis buf-
fer (RLT buffer) for total RNA extraction using RNeasy
Micro Kit (#74004; Qiagen). Quality and quantity of total
RNA was analysed on Nanodrop 1000 spectrophotometer
and Agilent BioAnalyzer prior to transcriptome profiling
using Illumina genome-wide gene expression Human
HT-12 v4.0 Expression BeadChip surveying 47,231 tran-
scripts per sample (performed at Barts and The London
Genome Centre, core facility). The data from microarray
was analysed on Genome studio version 3 Gene Expres-
sion Module. Raw transcriptome data have been deposited
at NCBI’s GEO database (GSE89217).
Results
Physical characterisation and verification of Exosomal
proteins
To confirm exosomal particle size, shape, membrane
structure and particle concentrations, we have used a
number of different techniques (Fig. 1) including scanning
electron microscopy (SEM; Fig. 1a), transmission electron
microscopy (TEM; Fig. 1b), Zetasizer (Fig. 1c) and
Nanoparticle Tracking Analysis (NTA; Fig. 1d). SEM
showed that exosomal sample appeared in clumps and
particle size (~ 30–100 nm) appeared to be on average
smaller than those measured by TEM (median ~ 50–
150 nm), Zetasizer (median ~ 50–150 nm) and NTA
(median 30–200 nm). As SEM were not able to reveal in-
ternal structures (Fig. 1a), we used TEM to confirm that
exosomes were circular membranous structures (Fig. 1b).
The Zetasizer system determines particle size by measuring
particle Brownian motion in suspension, using dynamic
light scattering for particles sizes from 0.3 nm to 10 μm.
For differential ultracentrifugation, cell debris and apoptotic
bodies (1–5 μm) are pelleted at 500×g centrifugation.
Microvesicles (200–800 nm) are pelleted at 16,500×g and
exosomes (30–200 nm) at 118,000×g (Fig. 1c). Finally we
used NTA to measure each of the 8 different types of exo-
somes derived from 3 normal oral keratinocytes (OK113,
NK4, NOK368) and 5 malignant (Ca1, CaLH2, SQCC/Y1,
SVpgC2a and SVFN8) cell lines. Exosomes from these cell
lines showed median sizes ranging from 76 to 136 nm (Fig.
1d) which are consistent with published findings [22]. We
did not see any significant physical differences between nor-
mal and cancer exosomes. However, we did notice that
TEM imaging showed slightly smaller exosome sizes com-
pared to NTA and Zetasizer. This could be due to differ-
ences in sample processing where TEM required exosomes
to be dried down before imaging.
Purity of exosomes were further verified by immuno-
blotting for exosomal specific and non-specific proteins.
ALIX is an exosomal specific membrane protein and a
component of ESCRTiii complex and is involved in the
biogenesis of exosomes [5]. It was expressed in exosomes
derived from all the eight cell lines at the molecular
weight of 102 kDa (Fig. 2a), indicating successful isolation
of exosomes. In order to rule out extravesicular protein
contamination, calnexin, an endoplasmic reticulum pro-
tein aiding in proper protein folding [23], was used to in-
vestigate the purity of exosomes. Ideally the expression of
calnexin should be absent from exosomes since they lack
the endoplasmic reticulum machinery. Calnexin was
expressed in all parental whole cell lysates at the molecu-
lar weight of 90 kDa, while the expression was very low to
absent in the exosome samples, verifying that our exo-
somes are relatively clean and free from contaminations.
Heat shock protein HSC70 (70 kDa) and Glyceraldehyde
3-phosphate dehydrogenase GAPDH (37 kDa) were used
as loading controls (Fig. 2a).
Tetraspanin proteins including CD63, CD9 and CD81
have been reported as exosomal specific membrane pro-
teins [24]. In our study we looked for the expression of
CD63 (63 kDa) and CD9 (25 kDa) in parental cell lysates
and exosomes. We detected CD63 and CD9 proteins in
parental cell lysates but in exosomes were almost un-
detectable despite at maximum protein loading (40 μg/
lane) and using highly sensitive detection system (data
not shown). Further exploration of the literature indi-
cates that these markers were reported from studies car-
ried out on immune exosomes derived from mast and
dendritic cells [25]. Hence, we conclude that there may
be variations in these different surface protein markers
depending on the origin of parental cell types.
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CEP55 is a potential cancer exosomal membrane marker
We have previously published that CEP55 is a down-
stream target of FOXM1 oncogene [11, 12] and that
CEP55 has been shown to be associated with ALIX and
the ESCRT complex [10, 26], we therefore asked if
CEP55 protein may be enriched in cancer exosomes as it
is known to be upregulated in cancer cells [11, 12, 27].
As expected, the expression of CEP55 protein was found
exclusively in exosomes derived from all 5 malignant cell
lines and absent from the 3 normal primary oral kerati-
nocytes (Fig. 2a). Within the parental cell lines, CEP55
expressed as doublet at the molecular weight of 55 kDa.
In order to verify the specificity of our antibody and ex-
clude non-specific binding, CEP55 was knocked down in
SVFN8 cells by siRNA transfection (Fig. 2b). The suc-
cessful knockdown of CEP55 mRNA in siCEP55 trans-
fected SVFN8 cells was validated by RT-qPCR (Fig. 2c).
Silencing of CEP55 protein by siCEP55 led to the dis-
appearance of the top band (Fig. 2b) indicating that the
top band was the correct CEP55 protein band. Given
that CEP55 protein was found to be enriched in exo-
somes from cancer cell lines, we further investigated if
this protein was specific to cancer exosomes or
non-specifically co-purified with exosomes. We therefore
performed immuno-gold TEM on exosomes to directly
visualise CEP55 protein in exosomes isolated from a
normal healthy blood plasma, normal oral keratinocyte
cell line (OK113) and two malignant cell lines (SVFN8
and SqCC/Y1; Fig. 2d). Exosomes were incubated with
CEP55 antibody and the gold labels were primed against
CEP55 antibody. Immuno-TEM images showed that
CEP55 gold labels appeared to be clustered by debris (<
15 nm diameter; Fig. 2d) in normal plasma and OK113
exosomes while SVFN8 and SqCC/Y1 exosomes showed
Fig. 1 Physical characterisation of exosomal size and concentrations. a scanning electron microscopy at low magnification (left panel) and a
subset showing high magnification (right panel) showing approximate diameters of each particle. b Transmission electron microscopy at low
magnification (left panel) and a subset showing high magnification (right panel), note the arrows indicating lipid-bilayer membrane structure.
c Zetasizer measurements on exosomes (Exo), microvesicles (MV) and cell debris (CD) fractions of two cell lines SVpgC2a and SVFN8. d NanoSight
particle analysis on exosomes derived from 3 normal primary human oral keratinocytes (OK113, NK4 and NOK368) and 5 malignant (Ca1, CaLH2,
SqCC/Y1, SVpgC2a and SVFN8) HNSCC cell lines. Numbers indicated within the diagram indicates the peak size (nm)
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CEP55 gold labels appeared on the outer membrane of
exosomes. Although not quantitative, these results pro-
vided qualitative confirmation that CEP55 could be a
specific cancer exosomal membrane marker. Whilst this
is beyond the scope of the current study, further valid-
ation on clinical specimens are required.
Verification of RNA cargos of exosomes
Free RNA or complexes containing RNA may be
co-precipitated alongside exosomes during ultracentrifu-
gation. To confirm that RNA cargos of exosomes are
protected against RNase digestion (Fig. 3a), we per-
formed RNase and ProteinaseK protection assays on
purified exosomes. Using Agilent BioAnalyzer analysis,
we confirmed that exosomal RNA remained intact (<
200 bp) following incubation with RNaseA (Fig. 3b).
Addition of TritonX to exosomes disrupted exosomal
membranes rendering exosomal RNA susceptible to
RNaseA digestion. Interestingly, we also found that
addition of ProteinaseK to exosomes also rendered
exosomal RNA partially susceptible to RNaseA diges-
tion. We hypothesised that ProteinaseK may digest exoso-
mal membrane proteins thereby perforating exosomal
membrane rendering RNA cargo susceptible to RNaseA
digestion. Having verified that RNA cargos were indeed
protected within exosomes, we asked whether mRNAs
were protected and found within exosomes. We have
chosen SVpgC2a (a premalignant cell line) and SVFN8 (a
malignant cell line derived from SVpgC2a, constitutively
expressing FOXM1) [12]. SVpgC2a expresses low levels of
FOXM1 oncogene whilst SVFN8 expresses high levels of
FOXM1. We compared cell debris and exosomes purified
from supernatant of these two cell lines, following the same
RNase and ProteinaseK protection assays as shown in Fig.
2b, we performed RT-qPCR to measure the levels of
FOXM1, ITGB1 and GAPDH mRNA (Fig. 3c). FOXM1,
ITGB1 and GAPDH mRNA purified from cell debris
fraction were all susceptible to RNaseA and ProteinaseK,
indicating that mRNA were not protected within vesicles.
On the other hand, we found that FOXM1 and GAPDH,
but not ITGB1, mRNAs were resistant to RNase digestion.
We also screened for other oncogenes including FOXM1B,
HOXA7, CCNB1, CENPA, DNMT3B, DNMT1, CEP55,
NEK2, HELLS, and BMI1. We found low levels of mRNA
protected within exosomes treated with RNase. Of these,
FOXM1B and HOXA7 mRNA levels were more abundant
in SVFN8 exosomes compared to SVpgC2a exosomes.
Whereas MAPK8, AURKA and ITGB1 mRNA were de-
graded with RNase treatment suggesting they were not car-
gos of exosomes but co-purify with protein aggregates
Fig. 2 Differential expression of CEP55 in normal and cancer derived exosomes. a Immunoblotting for exosomal proteins in normal (NOK368,
OK113, NK4) and malignant (SqCC/Y1, CaLH2, Ca1, SVpgC2a, SVFN8) cell-derived exosomes (top panel) and parental cells (bottom panel). ALIX,
exosomal protein; Calnexin, endosomal protein; GAPDH and HSC70 were used as loading controls. b Verification of CEP55 antibody specificity
using siRNA on SVFN8 cell line which expresses high levels of CEP55. HSC70 was used as a loading control. c RT-qPCR confirmed that siCEP55,
but not siCTRL, significantly (***P < 0.001) knocked down the mRNA of CEP55 in SVFN8. d CEP55 protein localisation studying using immunogold-
transmission electron microscopy on exosomes derived from normal human plasma, OK113, SVFN8 and SqCC/Y1 as indicated. Open arrow heads
indicate CEP55 protein gold labels (< 15 nm diameter including the halo around each black dot). Scale bars represent 30 nm
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Fig. 3 (See legend on next page.)
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during isolation (Additional file 1: Figure S1). Using differ-
ent qPCR primers to probe for the same mRNA transcript
(EGFP-FOXM1B) in exosomes, RT-qPCR results suggest
that EGFP-FOXM1B mRNA transcripts were full length
(Additional file 1: Figure S2A). We concluded that
exosomal mRNA is protected from extracellular environ-
ment including RNase and proteinase. Furthermore, we
demonstrated evidence of differential mRNA sorting
mechanism whereby some genes were preferentially pack-
aged within exosomes.
Transcriptome analysis on exosome transfected oral
keratinocytes
Having characterised and validated our exosomes, we in-
vestigated if these purified exosomes were functionally ac-
tive and could trigger a response in recipient normal oral
keratinocytes. Our preliminary experiments involved
transfecting exosomes, derived from a premalignant
SVpgC2a and a malignant SVFN8, on SVpgC2a as recipi-
ent cells. We found that exosomes from SVFN8 (contain-
ing high levels of EGFP-FOXM1B mRNA cargo;
Additional file 1: Figure S2A), but not SVpgC2a, triggered
an obvious morphological change resembling senescence
and/or differentiation within 24 h following transfection
in SVpgC2a cells (Additional file 1: Figure S3A). We con-
firmed the transfer of mRNA cargo (EGFP-FOXM1B) into
recipient cells using qRT-PCR to detect EGFP (Additional
file 1: Figure S2B) but it was surprisingly low levels and
transient (only detectable at 24 and 48 h, but not 72 or
96 h following transfection, data not shown). This led us
to investigate if exosome exposure trigger cell senescence
and/or differentiation in recipient cells. No evidence of
senescence associated β-galactosidase activity nor signifi-
cant mRNA modulation of senescence/apoptotic genes
p53, p21, p16 and CBX7 suggesting that recipient cells
were not undergoing senescence following exosome ex-
posure (Additional file 1: Figure S3B). Instead, we found
some evidence that mRNA of differentiation markers cor-
nifin (CORN) and loricrin (LORI) were perturbed, but not
involucrin (IVL) or transglutaminase 1 (TGM1), in recipi-
ent SVpgC2a cells indicating exosomes does not directly
activate differentiation but may have some roles in modu-
lating differentiation (Additional file 1: Figure S3C). As
these data provided incomplete picture, we therefore
opted for transcriptome analysis.
To our knowledge at the time of this study, no publica-
tion has compared transcriptomes of primary normal hu-
man oral keratinocyte cells transfected with normal or
cancer exosomes. Using microarray, we investigated the
global gene expression profile (47,231 genes) in an unbiased
way to understand the functional effects in recipient cells
exposed to normal vs cancer exosomes. Exosomes isolated
from normal primary human oral keratinocytes (OK113,
NK4, NOK368), HNSCC tumour-derived cell lines (Ca1,
CaLH2, SqCC/Y1), premalignant buccal oral keratinocytes
(SVpgC2a) and transformed malignant cell line (SVFN8),
were transfected onto OK113 cells for 48 h in serum free
medium prior to harvest. Un-transfected OK113 cells were
used as a control. When comparing untransfected cells
with all exosome-transfected cells, within the top 400
differentially expressed genes, 61.6% genes were downregu-
lated and 38.4% were upregulated (Fig. 4b). But when com-
paring between cancer and normal exosome-transfected
cells, within the top 400 differentially expressed genes, can-
cer and normal exosomes induced almost equal proportion
(50.3 vs 49.7%) of differentially expressed genes in recipient
cells (Fig. 4c). Correlation box-whisker plot between
untransfected vs exosome-transfected cells showed
significantly larger differential gene expression (Fig. 5a)
compared to that between cancer vs normal exosome
transfected cells (Fig. 5b), indicating that exposure to
either normal or cancer exosomes triggered significant
change in the transcriptome of recipient cells. We
further studied the differential gene expression between
normal vs cancer exosomes-transfected cells and found
that cancer exosomes indeed triggered different sets of
genes to those triggered by normal exosomes.
Within the top 50 upregulated and downregulated genes
in untransfected vs transfected (Fig. 5a) and in cancer vs
normal (Fig. 5b), 7–10 genes were selected from each cat-
egory (total 34 genes) for further validation by RT-qPCR
(Fig. 6a, b) using the same RNA samples used for tran-
scriptome analysis. Of the 34 candidate genes, we found
that only 19 genes were in agreement with the transcrip-
tome data. Their associated gene functions were listed in
Fig. 6c. Of these genes, we further selected 8 genes for
exosome dose- and time-response on independent OK113
transfection experiments (using OK113 and SqCC/Y1 de-
rived exosomes) to confirm their functional specificity.
We found a mixture of dose and time-dependent gene
(See figure on previous page.)
Fig. 3 RNA cargo of exosomes is protected from RNase. a schematics showing that RNA molecules are protected within intact exosomal
membranes which is resistant to RNase activity. TritonX disrupts exosomal membranes and thereby rendering RNA cargos susceptible to RNase
digestion. Digestion of membrane ProteinaseK may perforate membrane proteins thereby rendering RNA cargo susceptible to RNase digestion.
b Exosomal RNA quantification and quality confirmation (using Agilent BioAnalyzer 6000 Pico Kit) showing that majority of exosomal RNA are
below 200 bp and are resistant to RNase digestion until addition of TritonX and/or ProteinaseK. c RT-qPCR confirmed differential mRNA sorting
into exosomes. FOXM1, but not ITGB1, were found to be specifically packaged within exosomes (therefore resistant to RNase digestion). FOXM1
(isoform B) is constitutively overexpressed in SVFN8 cell line. ***P < 0.001 indicates statistically different from control
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expression patterns for different genes responding to dif-
ferent exosomes. For MMP9 and PGAM1, both normal
(OK113) and cancer (SqCC/Y1) exosomes triggered
dose-dependent upregulation of MMP9 and PGAM1, but
cancer exosomes were significantly more potent than nor-
mal exosomes (Fig. 7a). Conversely, cancer exosomes trig-
gered dose-dependent inhibition of BBOX1 and EFEMP1.
Both normal and cancer exosomes activated SPPR2E but
cancer exosomes were significantly less potent than nor-
mal exosomes (Fig. 7a). Interestingly, cancer exosomes
triggered a time-dependent bi-phasic effects on TSC22D3
and EEF2K gene expression whereby at 24 h incubation,
they were dose-dependently upregulated but were then
downregulated at 48 h incubation with cancer exosomes
(Fig. 7a). Neither normal nor cancer (SqCC/Y1) exosomes
had any significant effects on IGFBP3 gene expression.
Figure 7b summarised the differential mRNA expression
ratios of each gene, based on data presented in Fig. 7a.
Discussion
To our knowledge, this is the first study characterising
exosomes secreted from primary human oral keratino-
cytes and compared with exosomes derived from HNSCC
cell lines. Exosomes purified through differential ultracen-
trifugation from 3 different strains of primary normal
human oral keratinocytes and 5 malignant cell lines were
subjected to various nanoparticle characterisation
methods including scanning electron microscopy, trans-
mission electron microscopy, dynamic light scattering
(Zetasizer), 3D Brownian motion (NTA) and biochemical
membrane protein and mRNA cargo characterisations. All
physical characteristics of our purified exosomes were
consistent with published data [18, 22].
During characterisation of exosomal proteins, we acci-
dentally identified a potential unique cancer exosomal
membrane protein, CEP55, which were present in all 5
cancer exosomes and absent in all 3 normal exosomes
Fig. 4 Genome-wide gene expression analysis on normal primary human oral keratinocytes transfected by normal or cancer-derived exosomes.
a OK113 cells were transfected by equal concentration (2 × 1010 particles/well) of each type of exosomes for 48 h prior to microarray analysis using
Illumina Human HT-12 v4 Gene Expression BeadChip, exploring 47,231 genes. b Within the top 400 differentially expressed genes (P < 10− 20), exosome
(both normal and cancer) exposure led to larger proportion of downregulated genes (61.6%) compared with upregulated genes (38.4%) in recipient
cells. c Within the top 400 differentially expressed genes (P < 10− 2), cancer and normal exosomes induced almost equal proportion (50.3 vs 49.7%) of
differentially expressed genes in recipient cells
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(Fig. 2a). Further analysis using immune-gold TEM con-
firmed that CEP55 protein was located on the mem-
brane of cancer-derived but not normal exosomes (Fig.
2d). This appears to be consistent with the biosynthesis
of endosome involving the ESCRT (endosomal sorting
complex required for transport) membrane budding ma-
chinery [28]. CEP55 (55 kDa) is a centrosomal protein
involved in cytokinesis [29] and a known downstream
target of FOXM1 oncogene in HNSCC [30] and breast
cancer [31]. Crystal structural study revealed that CEP55
is a partner of ALIX in ESCRT complex [10] involved
membrane abscission during viral budding [26] and
exosomal budding into multivesicular endosomes [32].
Midbody (Flemming body) typically has a diameter of ~
1 μm and length of 3–5 μm [33] would have been re-
moved in our exosome purification protocol, hence we
could rule out midbody contamination in our exosome
preparation. There was also reports demonstrating
Fig. 5 Genome-wide differential gene expression analysis on normal primary human oral keratinocytes transfected by normal or cancer-derived
exosomes. a Correlation box-whisker plot between untransfected vs exosome (including both normal and cancer exosomes) transfected gene
expression profiles. b Correlation box-whisker plot between normal vs cancer exosome transfected gene expression profiles. Insets showing top
50 upregulated and top 50 downregulated genes, respectively
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ESCRT independent mechanism for budding exosomes
[32]. The presence of CEP55 on cancer exosomes but
not normal exosomes led us to suggest the involvement
of different endosome biosynthetic pathways. The mech-
anism of exosomal budding is beyond the scope of this
study, further investigations are required to delineate the
role of CEP55 in cancer exosomes.
Consistent with published studies that mRNA cargos
are protected within exosomes and resistant to RNase
degradation [2], we further showed that digestion of mem-
brane proteins by proteinaseK may render the RNA cargo
partially susceptible to RNase degradation presumably
because digestion of transmembrane proteins could
perforate the membrane of exosomes (Fig, 3a). When
screening for candidate mRNA transcripts packaged
within cancer exosomes, we found selective cargo loading
of certain mRNA transcripts within exosomes, thereby
providing evidence of selective sorting of mRNA into exo-
somes, consistent with existing data that protein and RNA
molecules are not randomly loaded into exosomes [34].
Nevertheless, we found evidence that full-length exogen-
ous transcripts were packaged within exosomes derived
from a cell line (SVFN8) constitutively overexpressing
EGFP-FOXM1B (Additional file 1: Figure S2A) and that
the mRNA cargo could be delivered into recipient cells
albeit transiently (Additional file 1: Figure S2B), consistent
with the finding that mRNA cargos are rapidly degraded
upon entry into recipient cells [35]. This has implications
in tailored engineering of specific exosomal cargos for
cancer therapeutics including self-homing targeted anti-
cancer drug delivery and cancer immunotherapy [36].
The morphological changes observed in recipient oral
keratinocytes transfected with cancer exosomes resem-
bled senescence but we could not find evidence of
Fig. 6 Verification of candidate gene differential expression using RT-qPCR on recipient OK113 cells. a Each bar represents differential mean ±
SEM gene expression (Log2 Ratio) of 8 exosomes (NOK368, OK113, NK4, SqCC/Y1, CaLH2, Ca1, SVpgC2a, SVFN8)-transfected OK113 compared with
untransfected OK113. b Each bar represents differential mean ± SEM gene expression (Log2 Ratio) of 5 cancer exosomes (SqCC/Y1, CaLH2, Ca1,
SVpgC2a, SVFN8)-transfected OK113 vs 3 normal exosomes (NOK368, OK113, NK4)-transfected OK113. Coloured bars (red for upregulated and
green for downregulated genes) represent differential expression patterns correlated with results obtained by microarray experiments in Fig. 5.
Grey bars represent insignificant and/or discordance expression patterns with results obtained by microarray. Statistical t-test *P < 0.05, **P < 0.01
and ***P < 0.001. c table listing all validated candidate genes with brief description of their putative functions. Further 8 genes were selected for
exosome time and dose-response analysis on OK113 cells in Fig. 7
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exosome-induced senescence as reported in other cell
systems [37]. Instead, we found some evidence of per-
turbed differentiation markers cornifin (CORN) and lori-
crin (LORI). As little is known about the functional
differences and molecular consequences of normal cells
responding to exosomes secreted by normal cells com-
pared to those secreted by cancer cells, we therefore per-
formed transcriptome profiling to investigate the global
gene expression profile (47,231 genes) in an unbiased way.
Transcriptome data showed that regardless of normal or
Fig. 7 Exosome time and dose-response effects on candidate genes (selected from Fig. 6) analysis on primary normal human oral keratinocytes
(OK113). OK113 cells were transfected by different doses (0, 50, 100, 200 μL) of exosomes derived from either OK113 or SqCC/Y1 HNSCC cells.
Transfected OK113 cells were harvested at two time points (24 h and 48 h) and RT-qPCR were performed to measure each target gene relative
expression. a Each bar represents mean ± SEM of relative gene expression (target:reference genes) at each exosome transfection time and dose
as indicated. b Each bar, derived from data presented in panel a, represents mean ± SEM of differential gene expression (Log2 Cancer:Normal
Ratio) between SqCC/Y1:OK113 exosome transfected OK113 cells at each time and dose of exosomes. Statistical t-test *P < 0.05, **P < 0.01
and ***P < 0.001
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cancer derived, exosomes altered molecular programmes
involved in matrix modulation (MMP9), cytoskeletal
remodelling (TUBB6, FEZ1, CCT6A), viral/dsRNA-in-
duced interferon (OAS1, IFI6), anti-inflammatory
(TSC22D3), deubiquitin (OTUD1), lipid metabolism
and membrane trafficking (BBOX1, LRP11, RAB6A).
Interestingly, cancer exosomes, but not normal exosomes,
modulated expression of matrix remodelling (EFEMP1,
DDK3, SPARC), cell cycle (EEF2K), membrane remodel-
ling (LAMP2, SRPX), differentiation (SPRR2E), apoptosis
(CTSC), transcription/translation (KLF6, PUS7). These
results indicated that cancer exosomes elicited additional
transcriptome programmes compared to normal exo-
somes. However, both normal and cancer exosomes in-
duced a subset of common pathways in recipient cells,
indicating a fundamental mechanism involved when
responding to any exosomes.
It has previously been shown that activated T cell
exosomes could upregulate MMP9 expression in murine
melanoma cells [38] and hepatocellular carcinoma-derived
exosomes could increase MMP9 secretion in hepatocytes
[39]. Upon further dose- and time-dependent exosome
transfection experiments validation by qRT-PCR, we
found that cancer exosomes induced stronger upregu-
lation of MMP9 and PGAM1 whilst suppressed
BBOX1 and EFEMP1, compared to normal exosomes.
Interestingly, TSC22D3 and EFF2K showed biphasic time-
dependent effects in respond to cancer exosomes.
Our results suggest that although some genes were
commonly modulated (eg., MMP9 and PGAM1 were
upregulated by both normal and cancer exosomes),
the effects were significantly amplified by cancer exo-
somes in recipient cells. Activation of MMP9 may
promote cell migration and invasion, whilst PGAM1
may reroute [40, 41] and/or uncouple glycolytic path-
ways to promote cell migration [42].
Apart from MMP9, none of the other genes (Fig. 6c)
had been previously associated with exosomes. BBOX1
has been shown to be essential for transport of fatty acids
across the mitochondrial membrane [43]. Through
meta-analysis of microarray data across 13 different types
of cancers, BBOX1 has been proposed to have an import-
ant role in cancer development [44]. EFEMP1, also known
as fibulin 3, is a member of the fibulin family of secreted
glycoprotein [45] known to regulate cell morphology, ad-
hesion, growth and motility [46]. Recently, upregulation of
EFEMP1 has been found in bladder cancer, correlating
with increased tumour invasiveness, while knockdown of
EFEMP1 restored the invasive and migratory potential
[47]. Another study showed that suppression of EFEMP1
reduced migration, invasion and promote apoptosis in
brain cells (glioma) [48]. Studies have also reported that
EFEMP1 regulates matrix metalloproteinase (MMPs) and
tissue inhibitors of MMPs [49]. Our finding that BBOX1
and EFEMP1 were suppressed by cancer exosomes may
indicate activation of a protective mechanism in the
recipient cells against potentially harmful cargos in cancer
exosomes [50].
SPRR2E is part of the human epidermal differentiation
complex on chromosome 1q21 and code for precursor
proteins of the cornified cell envelop, a structural char-
acteristic of terminally differentiated keratinocytes [51].
In a study on epidermal squamous cell carcinoma, low
expression of SPRR2 was noted in malignant keratino-
cyte cell lines compared to normal suggesting defective
terminal differentiation, a characteristic of carcinogenic
transformation [52]. Similar expression of SPRR2 has
been observed in neoplastic keratinocytes of the anal
track [53]. This is consistent with our finding that cancer
exosomes had significantly lower transactivation onSPRR2E
expression when compared to normal exosomes, suggesting
a role of cancer exosomes in antagonising differentiation in
recipient cells.
TSC22D3, also known as glucocorticoid-induced leu-
cine zipper (GILZ), is a potent anti-inflammatory protein
and plays a role in cell survival [54]. Previous studies
have reported increased expression of EEF2K in breast
cancer [55] and glioma [56], where it plays a critical role
in cell cycle, autophagy and apoptosis [57] making it a
potential target for cancer therapy. We found that both
TSC22D3 and EEF2K exhibited biphasic dose- and
time-dependent expression following cancer exosomes
transfection. Given their roles in regulating inflamma-
tion and apoptosis, their expression patterns in recipient
cells may indicate a complex dynamic network of inter-
acting signals responding to cancer exosomes.
Conclusion
This study provided evidence that both normal and
cancer exosomes modulated unique gene expression
pathways in normal recipient cells. Cancer cells may
exploit exosomes to confer transcriptome reprogram-
ming in recipient cells that leads to cancer-associated
pathologies such as angiogenesis, immune evasion/
modulation, cell fate alteration and metastasis. In
addition, we also demonstrated that malignant-cell de-
rived exosomes may express surrogate oncogenic
markers such as CEP55 membrane protein and carry
FOXM1 mRNA cargos. Based on our findings but
requires further validation study, we speculate that
exosomal CEP55 protein in saliva or blood could be
exploited as a cancer biomarker for non-invasive
mode of diagnosis and prognosis of HNSCC. In
addition, molecular pathways and biomarkers identi-
fied from our transcriptomics study may also be clin-
ically exploitable for developing novel liquid-biopsy
based diagnostics and immunotherapies.
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Additional file
Additional file 1: Figure S1. RT-qPCR confirmed differential mRNA
sorting into exosomes. Figure S2. Full length mRNA transcripts were
found in exosomes and could be transferred into recipient cells.
Figure S3. Exosomes induce morphological change within 24 h in
SVpgC2a recipient cells. (DOCX 981 kb)
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Methods and Materials 
Cell Culture 
Primary normal human oral keratinocytes (OK113, NOK368 and NK4) were extracted from normal oral 
mucosa tissue donated by disease-free individuals undergoing wisdom tooth extraction (kindly provided 
by Prof Daniela Costea, University of Bergen, Norway). Normal epidermal keratinocyte cell line N/TERT 
was derived from cells cultured from specimens of normal human epidermis (strain N). They have been 
immortalized by retroviral transduction of h-TERT, a telomerase catalytic subunit [1]. HNSCC derived 
cell lines Ca1, CaLH2, SqCC/Y1 were previously authenticated and have been used in multiple studies 
in our lab to represent disease state [2, 3]. SVpgC2a is a Simian virus 40 T-antigen-immortalised human 
buccal keratinocyte cell line, which retains a non-tumourogenic phenotype and can be used as a model 
of premalignant oral epithelium [4]. They express low levels of FOXM1 oncogene [2, 3]. SVFN8 cell line 
has been transformed from SVpgC2a by nicotine exposure and FOXM1 retroviral transduction (as a 
fusion EGFP-FOXM1B gene) hence overexpressing high levels of FOXM1 oncogene [2].  
Western blotting 
Samples were lysed in sample buffer (4% (w/v) SDS, 20% (v/v) glycerol and 0.125 M Tris-HCL at pH 
6.8). Samples were heated at 95ᵒC for 5 mins to denature the protein. Total protein concentration was 
measured using a BSA standard and the DCᵀᴹ Protein Assay (Bio-Rad, Hamel Hampstead, UK). The 
total protein was analysed using 10% (v/v) 2-merceptoethanol and 0.004% (w/v) bromophenol blue to 
the lysate and separated by SDS-PAGE (NuPage Novex 10% bis tris protein gels, 1.0mm, 10 wells). 
For both gel electrophoresis and the transfer the Novex mini cell system was used (Invitrogen, Paisley, 
UK). The membranes were blocked with 5% (w/v) fat-free milk for 30 mins and washed for 3x for 10 
mins each with TBS-T (20 mM Trizma base, 150 mM NaCl, 1% (v/v) Tween 20). Membranes were than 
probed with primary antibody (diluted in blocking buffer) overnight at 4°C and washed with TBS-T to 
prepare for incubation with secondary antibody (diluted in blocking buffer) for 1 hour at room temperature. 
Membranes were then washed again with TBS-T. Proteins were detected with Amersham ECL prime 
western blotting detection reagent (GE healthcare life sciences, Little Chalfont, UK). Peroxidase activity 
was measured in the dark room with autoradiography film (Amersham Hyperfilm ELC, GE Healthcare, 
Little Chalfont Bucks, UK).   
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Figure S1 - RT-qPCR confirmed differential mRNA sorting into exosomes. Exosomes purified from SVpgC2a 
and SVFN8 were subjected to RNaseA or TritonX (or both) treatments prior to RT-qPCR (SYBR Green 
method) for specific genes as indicated in each panel.  Each bar represents the mean ± SEM of quadruplicate 
determinations. All RNaseA + TritonX treatments led to complete RNA degradation (t-test P>0.001 for all 
RNaseA + TritonX vs RNaseA treated exosomes for all genes). 
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Figure S2 - Full length mRNA transcripts were found in exosomes and could be transferred into recipient cells. 
A, Using two sets of qPCR primers, one binding against the 3'-terminal of EGFP and the other binding against 
the 5'-terminal of FOXM1B transcript (as indicated in the diagram above the charts), RT-qPCR were performed 
on exosomes derived from either control cell line SVpgC2a (not transduced) or SVFN8 cell line constitutively 
expressing exogenous EGFP-FOXM1B transcripts (transduced with the retroviral vector expressing EGFP-
FOXM1B). Expression levels of both EGFP and FOXM1B were highly comparable indicating that the transcript 
EGFP-FOXM1B were intact. Exosomes derived from SVFN8 contained significantly higher levels of both 
EGFP and FOXM1B transcripts. B, SVpgC2a cells were either untransfected (+Media) or transfected with 
exosomes derived from SVpgC2a or SVFN8 for 24h prior to harvest for qRT-PCR to detect the presence of 
EGFP. Each bar represents a mean ± SEM of n=7 (for experiment in panel A) and n=11 (for B) independent 
experiments each performed with duplicate determinations. Statistical t-test *P<0.05, **P<0.01. 
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Figure S3 - Exosomes induce morphological change within 24hrs in SVpgC2a recipient cells. A, parental cell 
morphology, B, transfected SVpgC2a cells after 24hr of incubation with either SVpgC2a-derived exosomes or 
SVFN8-derived exosomes. Controls were treated with exosome-depleted supernatant, respectively as 
indicated. Scale bar indicates 30µm. C, Senescence/apoptotic marker genes mRNA were measured in 
untreated (open bars), SVpgC2a-exosomes (grey bars) or SVFN8-exosomes (black bars) transfected recipient 
cells (SVpgC2a). Orange bars indicate positive controls treated with etoposide (1x10-7 M for 24 hours) to induce 
senescence. D, Differentiation marker genes mRNA were measured in untreated, SVpgC2a-exosomes or 
SVFN8-exosomes transfected recipient cells (SVpgC2a). Orange bars indicate positive controls treated with 
CaCl2 (1 mM for 48 hours) to induce differentiation. **P<0.01. 
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